Medistim

M&A Activity • Nov 10, 2016

Medistim launches the SonoQ

Medistim launches the SonoQ

(Oslo, November 10th 2016), Medistim ASA (OSE: MEDI),

a medtech company that develops and distributes

surgical guidance and quality assessment devices,

launches the Medistim SonoQ.

In October 2015, Medistim entered into an exclusive

License and OEM agreement with em-tec GmbH, to market

and sell em-tec's transit time flow measurement (TTFM)

technology. This flowmeter is a basic solution that

suits price sensitive market segments and fills a gap

within Medistim's product portfolio. The first

Medistim labeled device based on this technology is

now being launched in selected markets.

The SonoQ is a device that accurately measures blood

flow intraoperatively. The features have been adapted

to address the specific needs of this market segment.

The system has a small footprint, and can easily be

shared between departments and operating rooms,

supporting high productivity in the hospital.

One of the most important target markets for the SonoQ

is India, a market with about 150,000 coronary artery

bypass procedures per year, which is very low compared

to the population size of 1.3 billion, and therefore

expected to grow. In collaboration with our local

distributor, Medistim is launching the new product at

the International Coronary Congress in New Delhi,

India, on November 11-13. This meeting is dedicated

to state of the art surgical coronary

revascularization, and the program highlights the

necessity of surgical guidance and quality assessment

based on intraoperative ultrasound and TTFM.

"While Medistim is the market leader with our own high-

end products for surgical guidance and blood flow

measurement in cardiac-, vascular and transplant

surgery, we have been lacking a basic TTFM system to

reach some emerging market segments," says Medistim

President and CEO, Kari E. Krogstad. "India is a

market where we have been present for years and

achieved occasional sales of our advanced products

VeriQ and MiraQ but we believe a lower price-point

solution is necessary to accelerate adoption both in

the private hospital chains and the public health

system. We look forward to continue our collaboration

with Indian surgeons and support their work to achieve

the best possible surgical outcomes."

About Medistim

Medistim is a medtech company that develops and

distributes ultrasound based surgical guidance and

quality assessment devices. With headquarters in

Oslo, Norway, Medistim was established in 1984, and

has a track record of profitable growth over the past

>10 years. The company is a pioneer within its

segment, and continues to invest in new product

development. Medistim has wholly owned subsidiaries

with sales organizations in the USA, Germany, UK,

Denmark and Norway, in addition to about 50

distributors in Europe, Asia, Middle East, Africa and

South America.

For more information, visit the Medistim home page:

www.medistim.com

For more information, contact:

President and CEO, Kari E. Krogstad, Medistim ASA

Tel: + 47 918 38 110

E-mail: kari.krogstad@medistim.com

CFO, Thomas Jakobsen, Medistim ASA

Tel: + 47 906 59 940

E-mail: thomas.jakobsen@medistim.com

This information is disclosed under Norwegian law

(Verdipapirhandelloven §5-12).